Sign Up to like & get
recommendations!
1
Published in 2023 at "CNS Spectrums"
DOI: 10.1017/s1092852923001797
Abstract: Abstract Introduction Patients with major depressive disorder (MDD) often have inadequate response to antidepressant treatment (ADT) requiring augmentation with other treatments. Cariprazine is a D3-preferring D3/D2 and serotonin 5-HT1A receptor partial agonist approved to treat…
read more here.
Keywords:
baseline;
adt;
cariprazine adt;
placebo ... See more keywords